Determination of telbivudine in the plasma of chronic hepatitis B patients in long‐term treatment by high‐performance liquid chromatographic–tandem mass spectrometry

Determination of telbivudine in the plasma of chronic hepatitis B patients in long‐term... Creatine kinase elevation is commonly reported in telbivudine‐treated patients. However, little is known about the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC‐MS/MS for the determination of telbivudine in a clinical study of chronic hepatitis B patients. The assay was linear in a dynamic 10–10,000 ng/mL range (r2> 0.999) and total analysis time was 6 min in this method. The validated method was applied to quantitatively determine plasma concentration in chronic hepatitis B patients during long‐term telbivudine treatment. The results revealed that telbivudine concentration in the creatine kinase‐elevated group (707.92–2788.78 ng/mL) was significantly higher than those with normal creatine kinase (412.63–1108.32 ng/mL). This method was adapted for therapeutic drug monitoring. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biomedical Chromatography Wiley

Determination of telbivudine in the plasma of chronic hepatitis B patients in long‐term treatment by high‐performance liquid chromatographic–tandem mass spectrometry

Loading next page...
 
/lp/wiley/determination-of-telbivudine-in-the-plasma-of-chronic-hepatitis-b-UHvXH0Di55
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons, Ltd.
ISSN
0269-3879
eISSN
1099-0801
D.O.I.
10.1002/bmc.4140
Publisher site
See Article on Publisher Site

Abstract

Creatine kinase elevation is commonly reported in telbivudine‐treated patients. However, little is known about the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC‐MS/MS for the determination of telbivudine in a clinical study of chronic hepatitis B patients. The assay was linear in a dynamic 10–10,000 ng/mL range (r2> 0.999) and total analysis time was 6 min in this method. The validated method was applied to quantitatively determine plasma concentration in chronic hepatitis B patients during long‐term telbivudine treatment. The results revealed that telbivudine concentration in the creatine kinase‐elevated group (707.92–2788.78 ng/mL) was significantly higher than those with normal creatine kinase (412.63–1108.32 ng/mL). This method was adapted for therapeutic drug monitoring.

Journal

Biomedical ChromatographyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off